Ann: RESETS BUSINESS WITH WRITE OFF OF INTANGIBLES & RESTRUCTURE, page-196

PTW - dose sales.
Now, come Jan 2018 if dose growth is back to well into double digits for the 2nd half of 2017, then high 20s should not be an issue. Any news of increased regulatory aspects in Japan or China would give a useful boost. Reimbursement in EU countries would be a +ve.

The real kicker will be the right-sided source for mCRC. If validated and recommended by NCCN and others then dose growth could easily be back to 20%+. This may be 12-24 months away. This aspect has the potential to take the SP above previous all time highs.

The outlier is the histone project - a long shot, but has the potential to make SRX a much larger company over the next few years. Trials will be measured in months (12-24), as opposed to years (8-10). All bets are off as to the impact, but the potential is huge, and would probably make SRX a very nice T/O target for a big pharma.